Is filgotinib included in medical insurance?

Filgotinib (Filgotinib) is a preferential JAK1 inhibitor that is metabolized to an active primary metabolite with similar JAK1 selectivity, but is 10 times less potent than the parent compound and has a relatively long elimination half-life. Figotinib 100 and 200 mg once-daily dosing are approved in Europe and Japan for the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC).

To date, filgotinib has been tested in various clinical studies in patients with rheumatoid arthritis, with doses of 100 to 200 mg given once daily or 50 to 100 mg twice daily effective against signs and symptoms, with rapid onset kinetics and a consistent safety profile. Of note, the DARWIN 2 trial examined filgotinib monotherapy, while other listed trials include filgotinib plus methotrexate. Figotinib 200 mg once daily is approved in Europe and Japan for the treatment of ulcerative colitis and is being evaluated in Phase III trials (100 and 200 mg once daily) for the treatment of Crohn's disease (CD).

The original drug of filgotinib has not yet been launched in China, so it is not included in medical insurance. Domestic patients cannot yet purchase this drug, and there is no way to reimburse it. The Bangladeshi version of the filgotinitine generic drug currently on the market overseas, specifications100mg*30 tablets may cost more than 500 yuan per box (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.